A phase 1 trial first-in-human, open-label, multicenter, single injection, dose-escalation study of EB-105 in patients with Diabetic Macular Edema (DME)
Latest Information Update: 12 Jun 2025
At a glance
- Drugs EB 105 (Primary)
- Indications Diabetic macular oedema
- Focus Adverse reactions; First in man; Pharmacodynamics
- Acronyms LOTUS
Most Recent Events
- 09 Jun 2025 According to an Eluminex Biosciences media release, Part 2 of this study will be conducted with multiple ascending doses in a similar DME population evaluating the same three dose levels as assessed in Part 1 and will be conducted at up to 10 sites in the United States,Expected to begin enrollment in Q3 2025.
- 09 Jun 2025 According to an Eluminex Biosciences media release, the study results (Part 1) ,will be presented at the Clinical Trials at the Summit annual meeting in Las Vegas, NV on June 21, 2025.
- 09 Jun 2025 Results (Part 1) from this study presented in the Eluminex Biosciences Media Release